GlassScriptPhysician profile
Frederick K Asare
NPI 1821195090
$85,962.96
in general payments reported to CMS, 2019-2025
29 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.10 · 2020: $578 · 2021: $313 · 2022: $12K · 2023: $18K · 2024: $28K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $72K · Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $71,853.23 |
| Food and Beverage | $1,395.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $83,275.53 | 2020-2025 | |
| Pfizer INC. | $456.97 | 2019-2025 | |
| Glaxosmithkline, LLC. | $358.80 | 2020-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $278.62 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $247.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $206.57 | 2024-2025 | Repatha, Otezla, Otezla |
| Supernus Pharmaceuticals, INC. | $131.58 | 2020 | |
| Janssen Pharmaceuticals, INC | $129.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $114.97 | 2020-2022 | |
| Exact Sciences Corporation | $84.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $79.62 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.28 | 2021-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $75.15 | 2020-2022 | |
| Amarin Pharma, INC. | $71.96 | 2020-2021 | |
| Abbvie INC. | $69.09 | 2021-2025 | Vraylar |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $64.58 | 2024-2025 | Mounjaro, Zepbound |
| Hikma Pharmaceuticals USA | $36.57 | 2019-2022 | |
| Eisai INC. | $31.25 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.01 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.99 | 2023 | Nuedexta |
| Paratek Pharmaceuticals, INC. | $20.56 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.92 | 2021 | |
| Dexcom, INC. | $16.51 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $14.70 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $14.26 | 2024 | |
| Medtronic, INC. | $14.22 | 2021 | |
| Biodelivery Sciences International, INC. | $12.24 | 2021 | |
| Merck Sharp & Dohme LLC | $11.77 | 2021 | |
| Phathom Pharmaceuticals, INC. | $4.90 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Asare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.